Status:
UNKNOWN
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
Lead Sponsor:
Bristlecone Health, Inc.
Collaborating Sponsors:
University of Minnesota
Conditions:
Diabetic Retinopathy (DR)
Age-related Macular Degeneration (AMD)
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The study will explore the impact of photobiomodulation (PBM), pulsating at frequencies of red (660nm) and near-infrared (810nm)(NIR), concurrent with a ketogenic dietary protocol (serum ketones @ .5 ...
Detailed Description
As part of the central nervous system (CNS), the retina shares key structural and functional features with the brain, making it a potential portal into a patient's medical future. Since the cerebral a...
Eligibility Criteria
Inclusion
- Male or Female (age 18-80)
- Previously diagnosed with MetS and/or T2DM as measured by possessing at least 2 of the following physiological measures: type II diabetes, BMI \>30, HgA1c \> 5.7, waist/height ratio \>.6, fasting glucose \> 125
- Previously diagnosed with at least one of the following: mid-peripheral drusen formation, diabetic retinopathy (DR), age-related macular degeneration (AMD) or diabetic macular edema
Exclusion
- Previously diagnosed with Alzheimer's disease (AD), dementia or Parkinson's disease
Key Trial Info
Start Date :
February 23 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03859245
Start Date
February 23 2019
End Date
September 30 2020
Last Update
March 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yankee Eye Clinic
Eagan, Minnesota, United States, 55123